Systemic Biologic Management of Atopic Dermatitis.
Adv Exp Med Biol
; 1447: 139-149, 2024.
Article
in En
| MEDLINE
| ID: mdl-38724791
ABSTRACT
Dupilumab and tralokinumab are currently the only FDA-approved biologic therapies for the treatment of moderate-to-severe atopic dermatitis. Tralokinumab is approved for patients greater than 18 years old, and dupilumab is approved for patients as young as 6 months old. Both medications are effective in clinical trials at improving atopic dermatitis. With a good safety profile and low-risk adverse events, dupilumab and tralokinumab are generally excellent treatment options for patients with severe or refractory atopic dermatitis.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Dermatitis, Atopic
/
Antibodies, Monoclonal, Humanized
/
Antibodies, Monoclonal
Limits:
Humans
Language:
En
Journal:
Adv Exp Med Biol
Year:
2024
Document type:
Article
Affiliation country: